Insulin Aspart Sanofi

Insulin Aspart, the active ingredient in Insulin Aspart Sanofi, is a rapid‑acting insulin analog presented as a sterile solution for subcutaneous use. It is used to control blood glucose levels in people with diabetes mellitus. GNH USA supplies Insulin Aspart Sanofi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin Aspart is a rapid‑acting insulin analog that lowers blood glucose by facilitating cellular uptake. - Type 1 diabetes mellitus: provides mealtime glucose control to match carbohydrate intake. - Type 2 diabetes mellitus: assists in post‑prandial glucose reduction when oral agents are insufficient. - Gestational diabetes mellitus: can be used under specialist supervision to achieve target glycaemia during pregnancy.

Adverse reactions may occur with any insulin therapy.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized fat tissue changes with repeated injections. - Weight gain: modest increase associated with improved glycaemic control.

Serious or Rare Side Effects: - Severe hypoglycaemia with neuroglycopenic symptoms requiring emergency assistance. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Hypersensitivity to excipients causing systemic symptoms. - Insulin antibody formation that may alter drug efficacy.

Insulin Aspart requires careful monitoring and patient education. - Dose adjustment: tailor dose based on blood glucose monitoring and carbohydrate intake. - Hypoglycaemia risk: educate patients on recognizing and treating low blood sugar. - Renal impairment: may need dose modification in severe kidney disease. - Pregnancy and lactation: use only if benefits outweigh potential risks and under medical supervision. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart can interact with several drug classes, affecting glucose control.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms and prolong its duration. - MAO‑A inhibitors: can potentiate insulin’s glucose‑lowering effect, increasing hypoglycaemia risk.

Moderate Interactions (Monitor Closely): - Oral hypoglycaemic agents (e.g., sulfonylureas, meglitinides): additive glucose‑lowering effect; monitor blood glucose closely. - Corticosteroids: may raise blood glucose, requiring insulin dose adjustments. - Thiazide diuretics: can cause hyperglycaemia, necessitating closer monitoring.